Vedolizumab prevented the postoperative recurrence of Crohn’s disease and should be considered a prophylactic treatment in ...

For many people with Crohn’s disease, reaching remission—when inflammation is no longer detectable—seems like a major victory ...

June 10, 2024 — Scientists have grown 'mini-guts' in the lab to help understand Crohn's disease, showing that 'switches' that modify DNA in gut cells play an ... Major Cause of Inflammatory ...

A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new ...

Lutikizumab is under clinical development by AbbVie and currently in Phase II for Crohn's Disease (Regional Enteritis).

A study by University of Michigan researchers may provide an explanation for why some patients with Crohn's disease continue ...

MetroCreative Inflammatory bowel disease (IBD) affects between 2.4 and 3.1 million people across the United States, according ...

Early treatment of pediatric Crohn's disease with anti-tumor necrosis factor medications can substantially reduce the risk of ...

Crohn's disease and ulcerative colitis are idiopathic, chronic, relapsing, inflammatory conditions that are immunologically mediated. Although their exact etiologies remain uncertain, results from ...

Tulisokibart is under clinical development by Merck and currently in Phase III for Crohn's Disease (Regional Enteritis).

If you recently learned that you have Crohn’s disease, you’re not alone. According to the National Institutes of Health, ...